|2.||Neoplasm Metastasis (Metastasis)
|3.||Breast Neoplasms (Breast Cancer)
|1.||Hortobagyi, Gabriel N: 307 articles (12/2015 - 01/2002)|
|2.||Dowsett, Mitch: 180 articles (11/2015 - 01/2002)|
|3.||Hankinson, Susan E: 175 articles (12/2015 - 02/2002)|
|4.||Perez, Edith A: 164 articles (12/2015 - 01/2002)|
|5.||Zheng, Wei: 162 articles (02/2016 - 07/2002)|
|6.||Noh, Dong-Young: 156 articles (12/2015 - 07/2002)|
|7.||Noguchi, Shinzaburo: 141 articles (01/2016 - 01/2002)|
|8.||Winer, Eric P: 141 articles (11/2015 - 06/2002)|
|9.||Hunt, Kelly K: 140 articles (11/2015 - 01/2002)|
|10.||Pusztai, Lajos: 139 articles (01/2016 - 04/2002)|
06/01/2009 - "Tamoxifen is a partial ER antagonist that is highly effective in the treatment of receptor positive breast cancer. "
04/01/2001 - "If women with a family history of breast cancer are being counseled regarding decisions on genetic testing, tamoxifen use, or other preventive measures, presenting both Claus and Gail estimates may be the best option."
08/01/2000 - "Tamoxifen is one of the most effective treatments for breast cancer. "
11/03/1999 - "Tamoxifen is most beneficial for younger women with an elevated risk of breast cancer. "
01/01/2014 - "Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not been widely embraced. "
|2.||trastuzumab (Herceptin)FDA Link
02/01/2009 - "Most studies presenting the frequently proposed threshold of QALY suggest that trastuzumab may be cost-effective for treatment of early breast cancer in a 1-year treatment regimen."
06/01/2002 - "Hopefully, information from these trials will help resolve questions regarding the efficacy of various combinations and dosing schedules so that trastuzumab may be used most effectively in the treatment of HER2-overexpressing breast cancer in both the metastatic and the adjuvant settings."
07/01/2015 - "Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer prognosis. "
07/01/2014 - "Trastuzumab has dramatically improved outcomes for those diagnosed with human EGFR2 (HER2)-positive breast cancer. "
02/01/2013 - "The best exemplar is HER2 positivity in breast cancer to determine the efficacy of Herceptin. "
|3.||Estrogens (Estrogen)FDA Link
03/01/2000 - "The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. "
05/01/1992 - "The results of this study with human breast cancer cells suggest that 5a may be highly effective in the treatment of estrogen-dependent breast cancer and/or in the prophylactic treatment of women with a high risk of breast cancer development."
01/01/2015 - "Because most of these Apiaceae spices are used widely with no known toxicity, the phytochemicals from the Apiaceae spices used in foods may be potentially protective against estrogen-mediated breast cancer."
08/23/2012 - "Endocrine therapies that inhibit estrogen receptor (ER)-α signaling are the most common and effective treatment for ER-α-positive breast cancer. "
06/15/2012 - "Although endocrine therapy has dramatically improved the treatment of breast cancer therapeutic resistance and tumour recurrence occurs, even in estrogen receptor (ER) positive cases. "
|4.||Paclitaxel (Taxol)FDA LinkGeneric
09/01/2005 - "Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks."
01/01/1993 - "Taxol is an important new antitumor agent with demonstrated efficacy in ovarian and breast cancer. "
01/01/2015 - "The restoration of Bak expression would be therapeutically beneficial for Taxol resistant breast cancer patients. "
01/01/2007 - "It is therefore concluded that paclitaxel in combination with seal oil demonstrated enhanced cytotoxicity and apoptosis in MCF-7 and MDA-MB-231 cells compared to paclitaxel alone, and the use of seal oil may be beneficial in the treatment of breast cancer."
02/15/2001 - "Significant influences on adoption included use of symposia as a therapy information source, physician experience with paclitaxel to treat late-stage breast cancer, and perceived advantage in efficacy of paclitaxel. "
01/01/2007 - "Our data indicate that hCG, like pregnancy, induces permanent genomic changes that are not reproduced by steroid hormones and in addition regulates gene expression through epigenetic mechanisms that are differentiation-dependent processes, leading us to conclude that hormonally induced differentiation offers enormous promise for the primary prevention of breast cancer."
02/07/2004 - "We report the findings of the safety analysis in HABITS (hormonal replacement therapy after breast cancer--is it safe?), an open randomised clinical trial with allocation to either HRT or best treatment without hormones. "
01/01/2003 - "The assessment of steroid hormone receptors in resected breast cancer tissues is essential to decide whether endocrine therapy is indicated and to select the best treatment for each patient on the basis of receptor status. "
08/01/2002 - "Currently it is the most widely used agent for first line treatment against hormone sensitive metastatic breast cancer and the only approved hormonal agent for adjuvant treatment of organ confined breast cancer. "
02/01/2016 - "Understanding the molecular pathways that regulate the hormone sensitivity of breast cancer cells is important to improving the efficacy of endocrine therapy. "
|6.||docetaxel (Taxotere)FDA Link
06/01/1999 - "Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). "
05/06/2003 - "Docetaxel (Taxotere), alone or in combination with other anticancer agents, has proven efficacy in the first- and second-line treatment of metastatic breast cancer. "
07/01/2002 - "Docetaxel has proven efficacy in metastatic breast cancer. "
09/01/2001 - "Although docetaxel (Taxotere; TXT), a taxoid anticancer drug, is clinically and experimentally very effective against breast cancer, its antitumor effect is of very short duration. "
04/01/2000 - "Docetaxel has proven effective in advanced breast cancer. "
|7.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/01/1996 - "The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support."
01/01/2015 - "For instance, Adriamycin (ADR) is beneficial for the treatment of breast cancer. "
09/01/2012 - "BACKGROUND/HYPOTHESES: Doxorubicin is a standard adjuvant therapy for early-stage breast cancer, and it significantly improves disease-free and overall survival. "
07/01/2013 - "Doxorubicin is effective against breast cancer, but its major side effect is cardiotoxicity. "
10/01/1987 - "It is concluded that when given at 3-weekly intervals adriamycin is a more effective treatment for advanced breast cancer at higher rather than lower dosage."
|8.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/01/2000 - "[Three cases of metastatic breast cancer, resistant to pre-chemo and/or endocrine therapy, markedly improved with UFT and cyclophosphamide oral combination therapy]."
05/01/2010 - "Compared with controls, both cyclophosphamide and CMF significantly improved disease-free survival and OS, and the benefits persisted for at least 25 years in premenopausal patients who had high-risk breast cancer."
12/15/1989 - "The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival."
01/01/2011 - "Increased efficacy and reduced cardiotoxicity of metronomic treatment with cyclophosphamide in rat breast cancer."
12/01/2007 - "Noninvasive assessment of (18)F-F-CP uptake using PET may potentially be helpful for predicting the response of breast tumors to cyclophosphamide before therapy begins."
|9.||capecitabine (Xeloda)FDA Link
08/01/2007 - "The oral fluoropyrimidine carbamate, capecitabine, is a highly active and well-tolerated treatment for metastatic breast cancer. "
01/01/2001 - "Capecitabine is an important new treatment option for breast cancer patients, and ongoing clinical trials should further define its role in a range of settings."
01/01/2012 - "Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer."
01/01/2012 - "We found significant improvement in the additional capecitabine arm versus control in disease-free survival (DFS) (HR = 0.83, 95% CI: 0.71-0.98, P = 0.027), overall survival (OS) (HR = 0.71, 95% CI: 0.57-0.88, P = 0.002), distant recurrence (HR = 0.79, 95% CI: 0.66-0.94, P = 0.008) and the death from breast cancer only (HR = 0.65, 95% CI: 0.51-0.83, P = 0.001). "
01/01/2010 - "Oral capecitabine (CAP) has shown significant benefits in early stage breast cancer (BC). "
06/01/2007 - "Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. "
01/01/2012 - "Aromatase inhibitors are very effective and safe in preventing recurrent disease in postmenopausal breast cancer. "
02/01/2008 - "Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease."
07/01/1999 - "The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in comparison with established second-line hormonal agents for advanced breast cancer in phase III clinical trials. "
01/01/2014 - "Major clinical trials and experimental studies showed that aromatase inhibitors are effective against postmenopausal breast cancer. "
|1.||Drug Therapy (Chemotherapy)
10/01/1995 - "To make legitimate the wide adoption of the strategy involving primary chemotherapy, most breast cancer specialists correctly advocate that the initial promising results be validated through classic randomized trials. "
05/01/2013 - "Currently, chemotherapy is one of the most effective treatments for breast cancer. "
04/01/2005 - "The TXL weekly regimen seems to be very effective in regressing breast tumors and can be given safely in the outpatient setting with an extremely high utility profile as neoadjuvant chemotherapy as well."
02/01/1996 - "Infusional ECarboF is a highly active, well-tolerated, outpatient regimen effective against advanced/metastatic breast cancer and now warrants evaluation against conventional chemotherapy in high-risk early breast cancer."
10/01/1995 - "Adjuvant therapy with either chemotherapy or hormonal therapy offers statistically significant benefits for most subsets of women with breast cancer that in many cases outweigh the risks of treatment, but the potential benefit will vary from patient to patient and by modality of therapy. "
01/01/1990 - "Adjuvant chemotherapy is a well accepted concept in the treatment of breast cancer and has resulted in most clinical studies in a significant prolongation of the disease-free interval in certain subgroups of patients. "
06/10/2015 - "A supervised, moderate- to high-intensity, combined resistance and aerobic exercise program is most effective for patients with breast cancer undergoing adjuvant chemotherapy. "
01/01/2006 - "Systemic adjuvant chemotherapy has dramatically improved the outcome of patients treated for early stage invasive breast cancer. "
12/01/2005 - "Adjuvant chemotherapy is most cost-effective in pre-menopausal women with node-positive breast cancer while cost-effectiveness decreases considerably with increasing age. "
01/01/2001 - "The proven benefits of adjuvant chemotherapy on disease-free and overall survival in breast cancer can be explained by concepts of cell kill. "
10/01/2011 - "The question whether and for whom the gold standard of whole breast radiotherapy (WBRT) may be replaced by accelerated partial breast irradiation (APBI) is one of the most controversial issue in the adjuvant breast cancer setting. "
09/01/2007 - "The findings of this study provide important information on QOL and their correlates among Nigerian women undergoing radiotherapy for breast cancer and are helpful in developing treatment strategies accordingly."
11/01/2015 - "The hypofractionated radiotherapy (AWB-RT treatment) is a new proven, safe and effective modality in post-operative patients with early breast cancer with excellent local control and survival. "
06/01/2009 - "Hypofractionation is a proven safe and effective modality for postoperative whole-breast radiotherapy for early breast cancer patients."
07/01/2015 - "Whether radiotherapy (RT) is beneficial in elderly (⩾ 70 years) patients undergoing conservative surgery for early breast cancer has long been controversial. "
10/01/2012 - "Preoperative breast magnetic resonance imaging (MRI) for patients with early-stage breast cancer has dramatically increased in use without the evidence of improved outcomes compared to standard assessment and is associated with higher rates of mastectomy. "
05/01/2003 - "Mastectomy and breast-conserving treatment have proven equally effective in terms of survival in early breast cancer, but studies continue to provide evidence that patients undergoing breast-conserving procedures have a better quality of life (QOL). "
08/01/2015 - "In patients with resectable locoregional breast cancer recurrences after mastectomy, multi-modal therapy comprising complete resection, radiation therapy in previously unirradiated patients, and systemic therapy results in 5-year disease-free and overall survival rates of 69% and 88%, respectively. "
03/01/2014 - "Since its introduction in 1991, skin-sparing mastectomy has emerged as an acceptable surgical technique in the management of breast cancer patients, providing optimal oncological safety and efficacy with favorable aesthetic results. "
03/01/2011 - "Breast cancer is now associated with long-term disease-free and overall survival, and in the setting of mastectomy, long term psycho-sexual health becomes an important consideration. "
|5.||Heterologous Transplantation (Xenotransplantation)
12/15/2015 - "We used patient-derived breast tumor xenografts (PDX) as high-fidelity preclinical models to determine the efficacy of single-agent or dual Ron/PI3K inhibition. "
09/01/2015 - "Alisertib enhanced MV oncolysis in vitro and significantly improved outcome in vivo against breast cancer xenografts. "
06/01/2008 - "We previously showed that AIIB2 had no discernible toxicity in mice; here, its addition allowed for a significant reduction in the IR dose that was necessary to achieve comparable growth inhibition and apoptosis in breast cancer xenografts in vivo."
08/01/2015 - "A treatment combination effective against malignant cells in spheroids also eliminated breast cancer cells from bone marrow in a mouse xenograft model. "
08/25/2014 - "Therapeutic efficacy of SN38-NPs was evaluated in xenograft balb/c animal with 4T1 breast cancer. "